Toyocamycin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Toyocamycin
Accession Number
DB13916
Type
Small Molecule
Groups
Experimental
Description

4-Amino-5-cyano-7-(D-ribofuranosyl)-7H- pyrrolo(2,3-d)pyrimidine. Antibiotic antimetabolite isolated from Streptomyces toyocaensis cultures. It is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.

Structure
Thumb
Synonyms
  • 4-amino-5-cyano-7-(D-ribofuranosyl)-7H-pyrrolo(2,3-d)pyrimidine
  • 7-deaza-7-cyanoadenosine
  • Ahygroscopin-B
  • Cyanotubericidin
  • Siromycin
  • Uramycin B
  • Vengicide
External IDs
A-399-Y4 / Antibiotic 1037 / Antibiotic A-399-Y4 / Antibiotic E212 / E-212
Categories
UNII
L7995C4D7F
CAS number
606-58-6
Weight
Average: 291.2627
Monoisotopic: 291.096753929
Chemical Formula
C12H13N5O4
InChI Key
XOKJUSAYZUAMGJ-WOUKDFQISA-N
InChI
InChI=1S/C12H13N5O4/c13-1-5-2-17(11-7(5)10(14)15-4-16-11)12-9(20)8(19)6(3-18)21-12/h2,4,6,8-9,12,18-20H,3H2,(H2,14,15,16)/t6-,8-,9-,12-/m1/s1
IUPAC Name
4-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
SMILES
NC1=C2C(=CN([[email protected]@H]3O[[email protected]](CO)[[email protected]@H](O)[[email protected]]3O)C2=NC=N1)C#N

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Toyocamycin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Toyocamycin.Experimental
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Toyocamycin.Approved, Investigational, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Toyocamycin.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Toyocamycin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Toyocamycin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Toyocamycin.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Toyocamycin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Toyocamycin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Toyocamycin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Toyocamycin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Toyocamycin.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Toyocamycin.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Toyocamycin.Experimental
LipegfilgrastimToyocamycin may increase the myelosuppressive activities of Lipegfilgrastim.Approved, Investigational
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Toyocamycin.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Toyocamycin.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Toyocamycin.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Toyocamycin.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Toyocamycin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Toyocamycin.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Toyocamycin.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
11331
BindingDB
50049823
ChEBI
134606
ChEMBL
CHEMBL99668
HET
TO1
PDB Entries
3re4

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.42 mg/mLALOGPS
logP-0.77ALOGPS
logP-1.4ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)12.46ChemAxon
pKa (Strongest Basic)4.71ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area150.44 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity71.09 m3·mol-1ChemAxon
Polarizability27.45 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on October 21, 2017 14:29 / Updated on March 02, 2018 04:33